Prevalence of toxoplasma, cytomegalovirus and rubella inpregnant women in Erzurum, Turkey

Aim: In this study, the seroprevalence of IgM- and IgG- type antibodies against Toxoplasma, Cytomegalovirus (CMV) and Rubellavirus was investigated in pregnant women with routine controls performed by family physicians in the city center of Erzurum in atwo-year period. It was aimed to compare the obtained data with other studies conducted in our country and in the world. Materials and Methods: The specific results of IgM and IgG serology of Toxoplasma, CMV and rubella of 6798 pregnant womenperformed by family physicians in the city center of Erzurum between 01.01.2018 and 31.12.2019 were investigated and evaluatedaccording to different age groups in this retrospective cross-sectional study. The serum samples were studied using the Architecti2000 systems with the Chemiluminescent Microparticle Immunoassay (CMIA) method in Erzurum Public Health MicrobiologyLaboratory.Results: The data of 6798 people between the ages of 15-50 were reached in our study. Toxoplasma, Rubella and CMV- (n = 6586)specific IgM antibody seropositivity rates were found as 0.5%, 0.3% and 0.6%, respectively, while Toxoplasma-, Rubella- and CMV specific IgG antibody seropositivity rates were found as 20.9%, 88.3% and 99.2%, respectively. Toxoplasma IgG seropositivity rateswere determined to increase in parallel with increasing age. Rubella IgG seropositivity rates were decreasing in the 15-24, 25-34 and35-49 age groups, respectively. The lowest Toxoplasma IgM and CMV IgM seropositivity rates were found in the 35-49 age groups. Conclusions: The two-year seroprevalence of Toxoplasma, CMV and Rubella was determined in pregnant women in our region withthis study. Although these seroprevalence rates in Erzurum are generally compatible with other studies conducted in our country,Toxoplasma IgM and rubella IgG seropositivity rates were found to be lower compared to the overall incidence of our country.

PDF

___

1. Inci A, Yener C, Guven D. The Investigation of toxoplasma, rubella and cytomegalovirus seroprevalancies in pregnant women in a state hospital. Pam Med J 2014;25:143-6.
2. Toklu GD. Antibodies frequency against Toxoplasmosis, Rubella Virus and Cytomegalovirus in pregnant women. J Clin Anal Med 2013;4:38-40.
3. Duran B, Toktamıs A, Erden O, et al. A Contraversial issue in antenatal care: TORCH screening. Cumhuriyet Med J 2002;24:185-90.
4. Altunal LN. Seroprevalence of Toxoplasma gondii, Rubella and Cytomegalovirus among pregnant refugees and Turkish women: a retrospective comparative study. South Clin Ist Euras 2018;29:235- 39.
5. Madendag Y, Eraslan Sahin M, Col Madendag I, et al. Investigation of toxoplasma, cytomegalovirus and rubella seroprevalence in pregnant women admitted to our hospital. Perinatal J 2018;26:7-10.
6. Sirin MC, Agus N, Yilmaz N, et al. Seroprevalence of Toxoplasma gondii, Rubella virus and Cytomegalovirus among pregnant women and the importance of avidity assays. Saudi Med J 2017;38:727-32.
7. Cicek AC, Duygu F, Inakcı IH, et al. Investigation of Toxoplasma gondii antibodies with ELISA among women of childbearing age in Sanlıurfa province: A three years evaluation. J Clin Exp Invest 2012;3:61-5.
8. Bakacak M, Bostancı MS, Kostu B, et al. Seroprevalance of Toxoplasma gondii, Rubella and Cytomegalovirus among pregnant women. Dicle Med J 2014;41:326- 31.
9. Obut M, Doğan Y, Bademkiran MH, et al. Toxoplasma, Rubella and Cytomegalovirus seroprevalence in pregnant women in Diyarbakir. Dicle Med J 2019;46:23-8.
10. Mumcuoglu I, Toyran A, Cetin F, et al. Evaluation of the toxoplasmosis seroprevalence in pregnant women and creating a diagnostic algorithm. Mikrobiyol Bul 2014;48:283-91.
11. Tanrıverdi EC, Kadioglu BG, Alay H, et al. Retrospective Evaluation of Anti-Toxoplasma gondii Antibody Among First Trimester Pregnant Women Admitted to Nenehatun Maternity Hospital between 2013-2017 in Erzurum. Turkiye Parazitol Derg 2018;42:101-5.
12. Ahmadpour GR, Ezatpour B, Hadighi R, et al. Seroepidemiology of Toxoplasma gondii infection in pregnant women in west Iran: determined by ELISA and PCR analysis. J Parasit Dis 2017;41:237-42.
13. El Deeb HK, Salah-Eldin H, Khodeer S, et al. Prevalence of Toxoplasma gondii infection in antenatal population in Menoufia governorate, Egypt. Acta Trop 2012;124:185-91.
14. Sahu SK, Pradhan SK, Nayak LM. Seroprevalence of TORCH infection among pregnant women. Int J Community Med Public Health 2019;6:2189-94.
15. Alghamdi J, Elamin MH, Alhabib S. Prevalence and genotyping of Toxoplasma gondii among Saudi pregnant women in Saudi Arabia. Saudi Pharm J 2016;24:645-51.
16. Tekin A, Deveci O, Yula E. The seroprevalence of antibodies against Toxoplasma gondii and Rubella virus among childbearing age women in Mardin province. J Clin Exp Invest 2010;1:81-5.
17. Inci M, Yagmur G, Aksebzeci T, et al. The investigation of Toxoplasma gondii seropositivity in women in the Kayseri province. Turkiye Parazitol Derg 2009;33:191- 4.
18. Zhang S, Hu L, Chen J, et al. Cytomegalovirus seroprevalence in pregnant women and association with adverse pregnancy/neonatal outcomes in Jiangsu Province, China. PLoS One 2014;9:e107645.
19. Sharma S, Duggal N, Agarwal S, et al. Seroprevalence of Toxoplasma, Rubella and CMV infections in antenatal women in a tertiary care hospital in North India. J Commun Dis 2015;47:23-6.
20. De Paschale M, Agrappi C, Manco MT, et al. Incidence and risk of cytomegalovirus infection during pregnancy in an urban area of Northern Italy. Infect Dis Obstet Gynecol 2009;2009:206505.
21. Kan O, Kocak O. Cytomegalovirus (CMV) screening results in pregnant women admitted to a tertiary center in the middle Anatolia. Turk Hij Den Biyol Derg 2019;76:423-30.
22. Enders G, Daiminger A, Lindemann L, et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. Med Microbiol Immunol 2012;201:303-9.
23. Pembrey L, Raynor P, Griffiths P, et al. Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One 2013;8:e81881.
24. Alvarado-Esquivel C, Terrones-Saldivar MDC, Hernandez-Tinoco J, et al. Seroepidemiology of Cytomegalovirus infection in pregnant women in the Central Mexican City of Aguascalientes. J Clin Med Res 2018;10:337-44.
25. Pradhan SV. Epidemiological and serological profiles of TORCH infection in pregnancy. J Pathology Nepal 2015;5:705-8.
26. Dempsey AF, Pangborn HM, Prosser LA. Costeffectiveness of routine vaccination of adolescent females against cytomegalovirus. Vaccine 2012;30:4060-6.
27. Gurlek B, Colak S. Antenatal Toxoplasma gondii, Rubella and Cytomegalovirus infection screening among pregnant women attending Tertiary University Hospital. Gynecol Obstet Reprod Med 2019;25:74-80.
28. Roomande N, Saremi A, Pooladi A, et al. Seroepidemiological study of Toxoplasma, Rubella, Cytomegalovirus and Varicella zoster in women; case study of Sarem Women’s Hospital. Sarem J Reprod Med 2019;3:65-9.
29. Muliyil DE, Singh P, Jois SK, et al. Seroprevalence of rubella among pregnant women in India, 2017. Vaccine 2018;36:7909-12.
30. Taku NA, Ndze VN, Abernathy E, et al. Seroprevalence of rubella virus antibodies among pregnant women in the Center and South-West regions of Cameroon. PLoS One 2019;14:e0225594.
31. Alvarado-Esquivel C, Hernandez-Tinoco J, SanchezAnguiano LF, et al. Rubella immune status in pregnant women in a Northern Mexican City. J Clin Med Res 2016;8:656-61.
32. Republic of Turkey Ministry of Health General Directorate of Primary Health Care Services. Extended immunization program circular. 2006 /Circular No: 120.